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Abstract:  
Abnormal self-renewal and differentiation are defining features of acute myeloid leukemia (AML).  Using 
models of hematopoiesis, we show that persistent self-renewal that ignores differentiation signals can be 
produced  through  two  distinct  pathways.   One  pathway  prevents  repression  of  stem  cell  genes, 
producing  daughter  cells  that  resemble  parental  stem  cells  despite  differentiation  inducing  lineage-
specifying  factor  or  cytokines.   Runx1 deficiency,  a  frequent  abnormality  in  AML,  demonstrates  the 
second pathway, which allows cytokine/lineage-specifying factor mediated repression of stem cell genes 
but impairs subsequent activation of differentiation genes that terminate transit-amplification, producing 
self-renewal in daughter cells that do not resemble the parental stem cell.  Use of this pathway by AML 
cells  has  therapeutic  relevance:  cell-fate  regulation  by  the  chromatin-modifying  protein  DNMT1  is 
differentiation-phase dependent.  In the post lineage-commitment differentiation-phase at which AML cell 
self-renewal occurs, DNMT1 has an opposite role than in normal stem cells.  Consequently, DNMT1 
depletion, using a clinically applicable method, terminates AML cell self-renewal but increases normal 
stem cell self-renewal.
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Introduction
Some cells in an acute myeloid leukemia (AML) clone self-renew in increased or unregulated 
fashion, driving clonal expansion.  Characterization of the mechanisms by which AML cells self-renew 
could lead to treatment that selectively destroys AML cells.  Current drug therapy mostly targets cellular 
components necessary for the health of both AML and normal dividing cells, causing significant toxicity 
often in return for only limited benefits.  
In the hierarchy of hematopoietic cells, hematopoietic stem cells are cells that exhibit self-renewal 
and multi-lineage differentiation.  Self-renewal is cell division that generates one or two daughter cells 
that resemble the parental stem cell.  Differentiation is cell division that generates one or two daughter 
cells that express high levels of lineage-specifying factors, and divide symmetrically to produce daughter 
cells that are advanced to the next differentiation level.  This process of exponential cell  expansion, 
called transit-amplification, ends when daughter cells arrive at the terminal differentiation state.  Since 
differentiating daughter  cells eventually exit  cell-cycle,  self-renewal by the hematopoietic stem cell  is 
necessary for clonal persistence.  
One approach to understanding AML cell  self-renewal  is  to  relate  it  to  pathways involved in 
normal stem cell function.  One potential pathway is deregulation of hematopoietic stem cell self-renewal, 
which is usually linear rather than exponential  .   With this pathway, self-renewing AML cells can be 
expected to phenocopy normal  hematopoietic stem cells,  and utilize molecular mechanisms for  self-
renewal  engaged by  normal  hematopoietic  stem cells  .   Another  potential  pathway,  proposed  as  a 
mechanism by which abnormalities of the  MLL gene can lead to leukemia , is acquisition in non-stem 
cells (for example, lineage-committed progenitors) of abnormalities that aberrantly activate stem cell self-
renewal pathways in the non-stem cell context.  Here, a third set of pathways were examined.  A defining 
feature of AML, which becomes quite obvious as clinically aggressive AML evolves from a preceding 
hematologic disorder known as myelodysplastic syndrome (MDS), is the accumulation of immature or 
differentiation-impaired hematopoietic cells (myeloblasts).  This suggests that differentiation impairment 
and abnormal self-renewal could have a cause-effect relationship .  We identified two distinct molecular 
pathways for producing self-renewal that ignores differentiation signals.  Interestingly, only one of these 
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pathways  widely  operates  in  AML.   Importantly,  this  pathway  produces  AML  self-renewal  in  a 
differentiation-context  distinct  from that  of  normal  stem cell  self-renewal,  such that  common cellular 
components have an opposite role in cell-fate regulation in the two contexts.  We demonstrate that one 
such component, the DNA methylating enzyme DNMT1, can be depleted using a clinically applicable 
method to concurrently increase normal stem cell and terminate AML cell self-renewal.  
Results
Lineage-specific  differentiation  requires  repression  of  stem cell  genes  prior  to  activation  of 
terminal differentiation genes.  Terminal hematopoietic differentiation depends on lineage-specifying 
transcription-factors  such as PU.1,  which  is  essential  for  producing macrophages.   PU.1,  like  other 
lineage-specifying  DNA binding factors,  demonstrates  both  transcription  repression and transcription 
activating functions, determined by interactions with either corepressors or coactivators (reviewed in ). 
The murine PUER cell-line is derived from Pu.1 knock-out hematopoietic precursors which have been 
transduced with a retroviral vector to express Pu.1 fused to the estrogen-receptor.  In cell-culture with 
mIL-3, PUER cells self-renew indefinitely.  Addition of tamoxifen (OHT) to these cells (as an estrogen 
agonist)  causes functional reintroduction of Pu.1 through translocation into the nucleus, and triggers 
terminal macrophage differentiation .  In PUER cells induced to differentiate by OHT, serial analysis of 
gene-expression by real-time quantitative polymerase chain reaction (RQ-PCR) demonstrated an early 
repression of genes associated with stem cells (HoxB4, Bmi-1, c-Kit) that was followed by activation of 
genes associated with terminal differentiation (Mcsfr, Gmcsfr, F4/80) (figure 1A). 
To  determine  if  the  initial  repression  of  stem  cell  genes  is  necessary  for  lineage-specific 
differentiation, DNA methyltransferase 1 (Dnmt1) was knocked-down by lentiviral transduction of shRNA 
(PUER shDnmt1).  Dnmt1 occupies a central  and critical position in the chromatin modifying protein 
network that mediates transcription repression .  In PUER shDnmt1 cells, Pu.1 mediated repression of 
stem cell associated genes was impaired and the cells continued to self-renew, implying that repression 
of stem cell genes is critical for initiation of differentiation (figure 1B).  
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To determine if the requirement for Dnmt1 activity is temporally confined to the initial phase in the 
differentiation-chronology, we used the United States Food and Drug Administration (FDA) approved 
drug decitabine to deplete Dnmt1 concurrent with Pu.1 activation or 6 hours after Pu.1.  Decitabine is a 
cytosine analogue that is incorporated into the newly synthesized DNA strand during the S-phase of cell-
cycle.  Dnmt1 is depleted by covalent modification and degradation when it attempts to methylate the 
DNA-incorporated decitabine.  Significant Dnmt1 depletion can be achieved with very small quantities of 
drug that do not cause measurable DNA damage, and which allow continued cell-division (figure S1A-
E).  Decitabine has no known effects other than depleting Dnmt1 and damaging DNA . 
As  expected,  decitabine addition  concurrent  with  Pu.1  prevented the repression of  stem cell 
associated  genes  and  maintained  self-renewal.   However,  decitabine  addition  6  hours  later,  after 
significant stem cell gene repression has already occurred, did not inhibit terminal differentiation (figure 
1C).
Similar  observations  were  seen using primary  human CD34+ hematopoietic  cells  induced to 
terminal  differentiation  by  the  granulocyte  differentiation  promoting  cytokine  granulocyte  colony-
stimulating  factor  (G-CSF).   Adding  decitabine  concurrent  with  G-CSF  prevents  stem  cell  gene 
repression  and  maintains  self-renewal  (figure  1D,  figure  S1F)  (previously,  we  demonstrated  that 
decitabine  treatment  prior  to  G-CSF  maintains  NOD-SCID  repopulating  activity  of  human  CD34+ 
hematopoietic stem cells ).  However, adding decitabine 6 hours after G-CSF is too late to prevent stem 
cell gene repression, and differentiation gene expression and terminal differentiation can proceed (figure 
1D, figure S1F).      
Therefore,  the  consequences  of  DNMT1  depletion  on  cell-fate  relate  to  the  differentiation-
chronology of sequential repression of key stem cell genes followed by activation of differentiation genes. 
DNMT1 depletion prior to or concurrent with a differentiation inducing stimulus prevents stem cell gene 
repression and maintains stem cell self-renewal.    
A  frequent  molecular  event  in  leukemogenesis,  deficiency  of  Runx1,  allows  stem  cell  gene 
repression and lineage-commitment but impairs activation of key terminal differentiation genes. 
To determine if genetic abnormalities in leukemia increase self-renewal and impair differentiation in a 
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manner similar to DNMT1 depletion, Runx1 was depleted in PUER cells.  Runx1 is a key transcription 
factor required for hematopoiesis.  Runx1 cooperates with lineage-specifying hematopoietic transcription 
factors, including Pu.1 and CEBP , to regulate gene-expression (reviewed in ).  Functional or actualα  
deficiency of RUNX1, by mutation or chromosome translocation of the RUNX1 gene, is one of the most 
frequent molecular events in hematologic malignancies (reviewed in ).  
Lentivirus  was  used  to  introduce  shRNA  for  Runx1  into  PUER  cells  (PUER  shRunx1).   In 
shRunx1 cells, Runx1 protein levels were <50% of that in empty vector transduced control cells (figure 
2A).   Unlike shDnmt1 cells,  repression of stem cell  genes is intact upon Pu.1 introduction in PUER 
shRunx1.  However, Pu.1 mediated activation of genes associated with differentiation is significantly 
impaired (figure 2B).  In micro-array gene expression analysis of multiple genes, genes repressed early 
after Pu.1 introduction into control cells were also significantly repressed in PUER shRunx1.  However, 
genes activated by Pu.1 in control cells had significantly impaired activation in PUER shRunx1 (figure 
S2A).   After  Pu.1  introduction,  PUER  shRunx1  continued  to  proliferate  with  minimal  morphologic 
changes despite repression of stem cell genes, exhibiting a significant growth advantage over control 
cells (figure 2C).  Therefore, the growth advantage of PUER shRunx1 cells over control PUER cells only 
became apparent in differentiation-promoting conditions.    
To extend these observations, lineage-negative hematopoietic stem cells isolated from the bone 
marrow of Runx1 haplo-insufficient mice (Runx1 +/-) (a gift of the Jim Downing laboratory ) were cultured 
with  self-renewal  promoting  cytokines   (stem  cell  factor  [SCF],  thrombopoietin)  or  differentiation 
promoting cytokines (SCF, interleukin 6 and G-CSF).  In self-renewal cytokines, both Runx1 +/- cells and 
control cells underwent minimal expansion (figure 2D).  However, in differentiation promoting cytokines, 
Runx1 +/- cells continued to expand exponentially for 14 days after cell counts in wild-type cells began to 
decline (figure 2D, figure S2B).  However, Runx1 abnormalities by themselves are insufficient to cause 
leukemia , and the Runx1 +/- cells in G-CSF eventually stop proliferating.  
RQ-PCR gene expression analysis  was used to analyze expression of  self-renewal,  lineage-
commitment and terminal differentiation genes in Runx1 +/- cells.  Hoxb4 promotes hematopoietic stem 
cell self-renewal .  Cebp  promotes granulocyte lineage-commitment in response to G-CSF.  Cebp  isα ε  
required for terminal granulocyte differentiation (reviewed in ).  Lineage negative Runx1 +/- cells and 
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wild-type control cells were cultured in media supplemented with G-CSF.  After 10 days of culture with G-
CSF, Runx1 +/- cells expressed higher levels of Cebp , but lower levels of Hoxb4 and Cebp , thanα ε  
wild-type cells, demonstrating that Runx1 deficiency allowed lineage-commitment (high Cebp  and highα  
Cebp /Hoxb4  ratio)  but  impaired  terminal  granulocyte  differentiation  (low  Cebp  and  lowα ε  
Cebp /Cebp  ratio) (ε α figure 2E).  
Therefore, unlike Dnmt1 deficiency, which increased self-renewal by preventing stem cell exit, 
Runx1  deficiency  allows  repression  of  stem  cell  genes  and  lineage-commitment,  but  impairs  the 
activation of key terminal differentiation genes that terminate the cell-division (transit-amplification) of 
lineage-committed cells.  Although this effect by itself is insufficient to produce the persistent unregulated 
self-renewal necessary for leukemia, possibly these abnormally proliferating linage-committed daughter 
cells could be the substrate for additional genetic or epigenetic abnormalities for evolution into leukemia. 
Transcript and epigenetic analysis of MDS and AML cells indicates progressive impairment of 
forward differentiation of lineage-committed cells.  If abnormal self-renewal in AML cells occurs in a 
post  lineage-commitment differentiation phase, AML cells from patients should express low levels of 
HOXB4  (which  promotes  stem  cell  self-renewal),  increased  levels  of  PU.1  and  CEBPα (lineage-
specifying factors associated with myeloid lineage-commitment), but relatively decreased levels of CEBP
ε (required for terminal granulocyte differentiation).    
To compare cellular  sub-sets with a similar  phenotype,  CD34+ cells were isolated from AML 
patient bone marrow (n=3) and normal donor bone marrow (n=3).  AML CD34+ cells expressed higher 
levels of CEBP , but lower levels of HOXB4 and CEBP , than normal CD34+ cells.  This is consistentα ε  
with  lineage-commitment  (high  CEBP  and  high  CEBP /HOXB4  ratio)  but  impaired  terminalα α  
granulocyte differentiation (low CEBP  and low CEBP /CEBP  ratio) in the AML CD34+ cells ε ε α  (figure 
3A, figure S3A).  The same pattern of gene expression was noted in AML CD34+ cells (n=10) compared 
to  normal  CD34+  cells   (n=11)  (figure  3B),  and  AML  myeloblasts  (n=311)  compared  to  normal 
myeloblasts  (n=3)   (cells  morphologically  at  the  same  level  of  differentiation),  analyzed  by  gene-
expression microarray (figure 3C) (raw data extracted from GEO Datasets).  HOXB4 expression data 
was not available in the micro-array gene expression analysis of myeloblasts.    
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AML arises through a multi-hit  process,  frequently  proceeding through an intermediate  stage 
called MDS.  Evolution of MDS to AML is marked by a progressive decrease in mature blood elements 
concurrent with an increase in morphologically immature myeloblasts.  To determine if this increase in 
immaturity  and  disease  aggressiveness  is  from  a  shift  towards  cells  with  stem  cell  phenotype 
(‘dedifferentiation’), or decreasing forward differentiation in lineage-committed cells, the transcript and 
DNA methylation profile in normal, MDS and AML bone marrow cells were compared.  
Lineage-specifying factor levels were measured by RQ-PCR in bone marrow aspirate cells from 
patients  with  low-risk MDS (<  5% myeloblasts,  4  cases) and patients  with high-risk MDS and AML 
(average myeloblast percentage 40%, 12 cases).  Controls were CD34+ selected cells and whole bone 
marrow  aspirates  from  normal  donors.   The  high-risk  samples,  although  morphologically  the  least 
mature, had the highest levels of the myeloid lineage-specifying factors CEBPα and PU.1 (figure 3D, 
figure S3B).  
DNA methylation of cytosines that precede guanines (CpG), catalyzed by DNMT, is an epigenetic 
mark associated with transcription repression.  Promoter CpG methylation patterns reflect the level of 
hematopoietic  differentiation  .   An  array-based  DNA  methylation  assay,  which  measures  DNA 
methylation at ~1500 CpG sites in the 5’-regulatory region of ~800 genes , was used to identify CpG 
which  undergo  significant  (p<0.001)  methylation  changes  between  normal  precursor  (CD34+)  and 
mature cells.  CpG with greater methylation (switched off) in mature cells are labeled precursor CpG (108 
CpG –  Table  S2A)  and CpG with  less  methylation  (switched on)  in  differentiated cells  are  labeled 
differentiation-CpG (162 CpG – Table S2B).  Methylation status was examined in 32 samples of low risk 
MDS and 132 samples of high risk MDS and AML  (patients described in ), and two in-vitro models of 
leukemia: CD34+ cells transduced with the AML fusion protein RUNX1-ETO as a leukemia first-hit or 
pre-leukemia  model  ,  and  the  RUNX1-ETO containing  Kasumi-1  cell-line  as  a  model  of  advanced 
transformation that initiates leukemia in transplanted mice .  Precursor CpG methylation increased from 
normal,  to  MDS,  to  AML.   Therefore,  the  increasing  morphologic  immaturity  was  not  from  ‘de-
differentiation’ or increasing stem cell phenotype.  Differentiation CpG methylation also increased from 
MDS to AML.  Taken together, this epigenetic profile suggests that increasing morphologic immaturity is 
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from increasing differentiation impairment that prevents forward differentiation of lineage-committed cells, 
rather than dedifferentiation or increase of stem cell phenotype (figure 3E).    
Therefore,  despite the diversity of  genetic and epigenetic abnormalities found in hundreds of 
cases of  MDS and AML,  the  transcript  and epigenetic  profile  indicates convergence during  disease 
evolution  onto  a  common  pathway  of  decreased  forward  differentiation  of  lineage-committed  cells. 
Furthermore,  the increase in  differentiation CpG methylation from MDS to AML suggests epigenetic 
mechanisms play a role in impairing forward differentiation of lineage-committed cells.  
    
The  opposite  cell  fate  consequences  in  response  to  DNMT1  depletion  in  AML  and  normal 
hematopoietic stem cells indicates AML cell self-renewal occurs in a post-lineage commitment 
differentiation phase.  In normal hematopoietic stem cells, DNMT1 depletion prior to or concurrent with 
a differentiation inducing cytokine or lineage-specifying factor, but not after, increases self-renewal by 
preventing  repression  of  stem  cell  genes.   Therefore,  if  AML  cells  self-renew  in  a  post  lineage-
commitment context, as suggested by the above analyses, then the functional consequences of DNMT1 
depletion should differ from that in normal hematopoietic stem cells.   
AML models were CD34 RUNX1-ETO and Kasumi-1 cells, and control cells were normal human 
CD34+ hematopoietic precursor cells isolated from cord-blood.  DNMT1 depletion by decitabine allowed 
continued proliferation of normal cells but diminished AML cell counts (figure 4A).  This contrasted with 
the effects of another clinically utilized cytosine analogue, cytosine arabinoside (Ara-C).  Ara-C is the 
mainstay of myeloid leukemia chemotherapy.  Ara-C does not deplete DNMT1 but  is a potent DNA 
damaging agent (figure S1B,C).  Ara-C, at the same molar concentration as the decitabine (0.5 µM), 
was toxic to both normal cells and AML cells (figure 4A).  
The  decitabine-induced  decrease  in  AML  cell-counts  was  not  via  apoptosis  (annexin/7AAD-
staining measured by flow-cytometry) (figure 4B).  Decitabine maintained primitive morphology of the 
normal cells but induced morphologic differentiation of the AML cells (decreased nuclear cytoplasmic 
ratio,  nuclear segmentation and condensation,  cytoplasmic granulation and vacuolation) (figure 4C). 
Decitabine treated normal CD34+ cells produced fewer colonies in semi-solid media than untreated cells, 
however, the colonies formed were larger and mixed.  Furthermore, decitabine treatment enabled colony 
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formation by normal cells even after  a prolonged period of  liquid culture,  which severely  diminished 
colony  formation by  untreated cells  (figure 4D)  (previously,  we demonstrated expanded NOD/SCID 
engraftment  potential  of  decitabine  treated  normal  CD34+ hematopoietic  precursors  ).   In  contrast, 
colony forming ability was abrogated in decitabine treated AML cells compared to untreated cells (figure 
4D,  figure  S4A).   Depletion  of  DNMT1 by  transfection  of  siRNA into  Kasumi-1  cells  also  induced 
differentiation and terminated proliferation (figure S4B,C,D).  
DNA  methylation  changes  induced  by  decitabine  treatment  were  measured  by  micro-array 
analysis (as described for figure 3).  In normal cells, but not in the AML cells, decitabine significantly 
decreased precursor-CpG methylation, consistent with the difference in produced functional phenotype 
(figure  4E).   In  both  normal  and  AML  cells,  decitabine  significantly  decreased  differentiation-CpG 
methylation, although this only triggered terminal differentiation in the AML cells (figure 4E).
The  cell-fate  consequences  in  response  to  DNMT1  depletion  can  distinguish  between  self-
renewal  in  a stem cell  context  or  aberrant  self-renewal  in  a post  lineage-commitment  differentiation 
phase.  In RUNX1-ETO containing AML cells, terminal differentiation in response to DNMT1 depletion is 
consistent with abnormal self-renewal post-lineage commitment.        
DNMT1 depletion with decitabine induces terminal differentiation of primary leukemia cells and 
cell-line models containing a variety of chromosome abnormalities.  The gene-expression and DNA 
methylation  profile  of  hundreds  of  MDS  and  AML  samples  suggests  that  self-renewal  in  lineage-
committed daughter cells occurs frequently in AML and is not confined to cases containing RUNX1-ETO. 
If so, terminal differentiation in response to DNMT1 depletion should be observed in AML cells containing 
different genetic abnormalities.  
Human  CD34+  hematopoietic  precursor  cells  isolated  from cord-blood  were  transduced  with 
retrovirus to express the leukemia fusion protein MLL-AF9.  The indefinitely self-renewing and leukemia-
initiating cells that arose from this transduction do not express CD34 and express high levels of lineage-
specifying factors, consistent with self-renewal in lineage-committed daughter cells (figure S5A,B).  Non-
DNA damaging levels of decitabine (figure S5C) deplete DNMT1 and induce terminal differentiation of 
MLL-AF9 cells, including MLL-AF9 cells co-transduced to express activated mutants of RAS and FLT3, 
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frequent cooperating events noted in AML (figure 5A).  Colony formation is a surrogate for leukemia-
initiating activity by MLL-AF9 cells .  DNMT1 depletion abrogates colony formation by viable MLL-AF9 
cells  (figure 5B)  (the  cells  were harvested from liquid culture  on day 5 while  there  were  still  large 
numbers  of  viable  cells,  there  were  no  viable  cells  by  day  14).   Identical  treatment  of  normal 
hematopoietic stem cells sustains colony forming ability for an extended period (figure 4D).  
Non-DNA damaging levels of decitabine were also used to deplete DNMT1 in the following AML 
variants:  primary leukemia cells from 14 patients with different patho-morphologic sub-types of AML 
containing a variety  of  chromosome abnormalities,  and the UT7 and K562 erythro-megakaryoblastic 
leukemia cell-lines which contain multiple chromosome abnormalities.  Decitabine 0.5 µM on day 1, 4 
and  7  induced  terminal  differentiation  in  12/14  patient  primary  leukemia  samples  and  in  both 
erythroblastic leukemia cell-lines (figure 5C).  
In different AML cases containing a variety of genetic abnormalities, the cell-fate consequences in 
response to DNMT1 depletion are consistent with the operation of a common pathway of abnormal self-
renewal in a post-lineage commitment context.  
A non-DNA damaging, DNMT1-depleting regimen of decitabine increases survival in a murine 
xeno-transplantation model of aggressive human leukemia.  Since decitabine is an FDA approved 
drug, the potential clinical relevance of the above findings was explored in a xeno-transplantation model 
of aggressive human AML.  Mice transplanted with 1x106 MLL-AF9 cells develop lethal invasive leukemia 
with a median survival of 5 weeks .  These mice were treated with a very low dose of decitabine to 
deplete  DNMT1  without  causing  DNA  damage  (0.3mg/kg  [~1mg/m2]).   A  frequent  but  intermittent 
schedule  of  drug  administration  was  used,  to  allow  cell-division,  since  this  should  trigger  terminal 
differentiation  in  leukemia cells  but  increase self-renewal  of  normal  hematopoietic  stem cells.   This 
contrasts with the usual intent with chemotherapy, which is to produce cytostasis or cytotoxicity.  The in-
vivo  DNMT1-depleting,  non-DNA  damaging  properties  of  the  regimen  were  confirmed  by  immuno-
fluorescence staining for DNMT1 and flow-cytometric measurement of phospho-H2AX in bone marrow 
cells  (figure  6A,B).   This  dose  and  schedule  of  decitabine  significantly  extended  murine  survival, 
although it did not cure the mice (figure 6C).       
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Discussion
Although AML is heterogeneous at the genetic and epigenetic level, most cases utilize a common 
pathway for abnormal self-renewal.  Possibly, only a few recurrent abnormalities initiate abnormal self-
renewal, and much of the genetic and epigenetic heterogeneity seen in AML relates to other aspects of 
neoplastic evolution.  For example,  RUNX1 and CEBPα abnormalities, both of which directly influence 
CEBPε expression and terminal myeloid differentiation (but not necessarily  lineage-commitment),  are 
detected in a substantial portion of MDS and AML cases (reviewed in ), and account for most familial 
MDS or AML  .    Presumably the utilization of this pathway for abnormal self-renewal has advantages 
over the others that have been proposed.     
A requirement for intact transcription repression machinery in the initial phase of differentiation 
(figure  6D)  explains  increased  self-renewal  of  hematopoietic  stem  cells  and  embryonic  stem  cells 
treated with inhibitors of histone deacetylase  and increased self-renewal of embryonic stem cells subject 
to knock-down or inhibition of DNMT .  Similarly, the described pathway for abnormal self-renewal in a 
post-lineage-commitment,  post  stem  cell  gene  repression  differentiation  phase,  explains  terminal 
differentiation of a variety of leukemia and cancer models in response to DNMT1 depletion and histone 
deacetylase inhibition (reviewed in ) (figure 6D).  
Although  DNMT1 and  the  histone  deacetylase  family  are  not  typical  oncogenes  or  tumor 
suppressor genes, they have an opposite role in cell-fate regulation in the context of AML versus normal 
stem cell self-renewal.  Clinically available drugs can be used to inhibit DNMT1 or histone deacetylase. 
Distinct from typical oncotherapeutic drug regimens, which intend cytostatic or cytotoxic effects, drug 
dose and schedule can be modified to allow cell-division, thereby terminally differentiating malignant cells 
and concurrently increasing self-renewal of normal stem cells.  The consequent decrease in toxicity may 
enable chronic treatment to maintain the therapeutic effect.   The mechanism of AML self-renewal is 
incentive  for  improving the dose,  schedule  or  pharmacology  of  existing  drugs,  and developing new 
agents, to target these components of the transcription repression machinery.    
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Not all cells in an AML clone have self-renewal capacity .  Two terms used in describing the 
heterogeneity of AML cell populations are cell  of origin (CO) and leukemia-initiating cells (LIC) (cells 
which initiate leukemia after transplantation into murine recipients) .  The CO is a cell that sustained the 
first-hit in a multi-hit process that leads to AML, and is probably a stem cell in most cases.  LIC can be 
separate  from  the  CO:  the  described  AML  pathway  promotes  abnormal  self-renewal  in  lineage-
committed daughter cells of the CO .  These abnormally self-renewing lineage-committed daughter cells 
of  a  stem cell  CO can  form  an  expanded  pool  of  cells  available  for  random additional  genetic  or 
epigenetic hits to evolve into LIC.  Therefore, secondary mutations implicated in LIC generation can be 
lineage-restricted despite evidence for a stem cell CO .  Consistent with this pathway for LIC generation, 
AML LIC frequently have a lineage-committed phenotype (CD34+CD38+ and CLL-1 expression) .  
One  caveat  to  the  proposed  treatment  approach  is  that  DNMT1  depletion  is  expected  to 
terminally differentiate LIC with features of lineage-commitment, but would not be expected to terminally 
differentiate CO or LIC which phenocopy hematopoietic stem cells.  In malignancies in which terminal 
differentiation responses appear intact, for example chronic phase chronic myeloid leukemia (CML), self-
renewal may utilize stem cell  associated pathways and not the described AML pathway.   However, 
transformation of CML into AML seems likely to utilize the described pathway, since CML blast crisis LIC 
demonstrate lineage-commitment . 
In  conclusion,  persistent  self-renewal  that  ignores  environmental  differentiation  cues  can  be 
produced via two distinguishable pathways.  One pathway generates daughter cells that resemble the 
parental  stem cell  (true self-renewal).   The second pathway converts transit-amplification of lineage-
committed  daughter  cells  into  abnormal  self-renewal.   AML  cells  exhibit  the  second  pathway. 
Importantly, common cellular components, such as elements of the transcription repression machinery, 
have differentiation-phase specific function, such that they have an opposite role in cell-fate regulation in 
the differentiation-phase at which AML self-renewal occurs compared to their role in normal stem cells. 
These cellular components can be targeted by clinically available drugs, to concurrently increase normal 
stem cell and terminate AML cell self-renewal. 
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Figure 1
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Figure 1.  Lineage-specific differentiation requires repression of genes associated with stem cells prior 
to  activation  of  genes  associated  with  terminal  differentiation. A) OHT 100nM  (which  functionally 
introduces  Pu.1)  mediated  differentiation  of  PUER  involves  stem  cell  gene  (Bmi1,  HoxB4,  cKit) 
repression followed by differentiation gene (Mcsfr, Gmcsfr, F4/80) activation (gene expression measured 
by  RQ-PCR).   B)  Dnmt1  suppression impairs  OHT (Pu.1)  mediated  stem cell  gene  repression and 
terminal  differentiation.   Dnmt1 expression in  PUER cells  was suppressed by shRNA.  Images:  phase-
contrast and Giemsa-stained cytospins of PUER 48h after OHT.  C) Dnmt1 depletion after the stem cell 
gene repression phase does not impair differentiation.  Decitabine (DAC) 0.5 µM was used to deplete 
Dnmt1 in  PUER cells  concurrent  with,  or  6 hours  after,  OHT differentiation  stimulus.   Gmcsfr  and Mcsfr 
expression were not measured in DAC 6h.  Images: 48h after OHT.  D) Decitabine effect on normal human 
CD34+ hematopoietic precursor cell-fate depends on timing of decitabine addition in relationship to a 
cytokine-mediated (G-CSF) differentiation stimulus.  G-CSF (100ng/ml)  was added to CD34+ selected 
cord-blood cells cultured in media supplemented with SCF, FLT3, TPO, IL-3 and IL-6.  DAC (0.5µM) was 
added either concurrently with G-CSF or 6 hours after G-CSF.  Images: day 7 after G-CSF.  Data for colony 
formation in semi-solid media are in figure S1.  
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Figure 2
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Figure 2.   Deficiency of Runx1 allows Pu.1 (OHT) mediated stem cell  gene repression but impairs 
activation of terminal differentiation genes.  A)  Lenti-viral transduction of shRNA suppresses Runx1 
protein expression in PUER cells (measured by Western blot).  B) shRunx1 allows Pu.1 mediated stem 
cell gene repression but impairs differentiation gene activation.  Gene expression measured by RQ-PCR. 
Results  of  micro-array  gene  expression  analysis  are  in  figure  S2.   C)   PUER  shRunx1  cells  retain 
proliferative capacity and undifferentiated morphology despite stem cell gene repression.  Cell-counts 
daily by automatic cell-counter.  Images: phase-contrast 24h after OHT. D)  Lineage negative hematopoietic 
stem cells isolated from the bone marrow of Runx1 +/- mice demonstrate a growth advantage over 
wild-type hematopoietic stem cells when cultured in differentiation promoting conditions (SCF, IL-6 and 
G-CSF) compared to self-renewal promoting conditions (SCF, thrombopoietin).  Images: colonies 14 days after 
plating bone marrow cells  isolated from Runx1 +/-  or  wild-type congenic  mice (2x104 cells/ml)  in  methyl-
cellulose supplemented with self-renewal or differentiation promoting cytokines. E)  Lineage-commitment but 
impaired terminal differentiation of Runx1 +/- cells demonstrated by the expression of Cebp , Hoxb4α  
and Cebpε.  Gene expression 10 days after culture of lineage-negative stem cells in SCF, IL-6 and G-CSF 
(bar-graphs).   The Cebp /Hoxb4 ratio  increases with lineage commitment,  and the Cebp /Cebp  ratioα ε α  
increases with terminal differentiation.       
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Figure 3
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Figure  3.   The  transcript  and epigenetic  profile  of  patient  AML cells  suggests  decreased forward 
differentiation of lineage-committed cells.  A) CD34+ AML cells express higher levels of CEBP , butα  
lower  levels  of  HOXB4  and  CEBP ,  than  normal  CD34+  hematopoietic  precursorsε .   The 
CEBP /HOXB4 and CEBP /  ratio were calculated in each sample as indices of lineage-commitment andα εα  
terminal differentiation respectively.  Gene expression by RQ-PCR.  Distribution of individual expression ratios 
represented by box-plot.  Clinical characteristics of patients in figure S3. B)  Similar findings for CD34+ AML 
cells  (n=10) and  normal  CD34+  cells (n=11)  analyzed  by  gene-expression  micro-array  (raw  data 
extracted from GEO Datasets).  Expression levels represented by heat-map.  C) AML myeloblasts (n=311) 
display lineage-commitment but impaired terminal differentiation compared to normal cells at different 
levels of differentiation (n=38), including normal myeloblasts (n=3)  (HOXB4 expression data not available 
for  this  Microarray  platform).  D)  Lineage-specifying  factor  levels  increase  from low risk  MDS (<5% 
myeloblasts) to high risk MDS and AML ( 5% myeloblasts) ≥ (measured by RQ-PCR).  Samples are bone 
marrow from normal donors, patients with low risk MDS (<5% myeloblasts), and high risk MDS/AML ( 5%≥  
myeloblasts).  Clinical characteristics of patients in figure S3.  E) Precursor CpG methylation increases from 
normal, to MDS, to AML, suggesting increasing morphologic immaturity is not from increasing stem 
cell phenotype.  Differentiation CpG methylation also increased from MDS to AML, suggesting a role 
for  DNA  methylation  in  differentiation-impairment  that  prevents  forward  differentiation  of  lineage-
committed cells.  CpG with greater methylation (p<0.001) (switched off) in normal mature cells are labeled 
precursor CpG (108 CpG – Table S2A) and CpG with less methylation (p<0.001) (switched on) in differentiated 
cells are labeled differentiation-CpG (162 CpG – Table S2B).  nCD34 = CD34+ cells isolated from normal bone 
marrow (n=9), nBM = normal whole bone marrow (n=42), LR-MDS = bone marrow from low-risk MDS patients 
(n=32), RAEBAML = bone marrow from high-risk MDS/AML (n=132) patients .   In-vitro models: nCD34 = 
CD34+ cells isolated from cord-blood, RUNX1-ETO = CD34+ hematopoietic precursors retrovirally transduced 
with RUNX1-ETO as a model of pre-leukemia, Kasumi1 =Leukemia cell line from patient with RUNX1-ETO 
leukemia. Box-plot boundaries = inter-quartile range, horizontal line = median, ‘+’ = mean, whiskers = range of 
values, small boxes = out-lying values.  
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Figure 4
Figure 4:  The opposite cell fate consequences in response to DNMT1 depletion in AML and normal 
hematopoietic  stem  cells  indicates  AML  cell  self-renewal  occurs  in  a  post-lineage  commitment 
differentiation phase.  Leukemia models: CD34+ cells transduced with RUNX1-ETO and Kasumi-1 cell-line. 
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Control: normal cord blood CD34+ cells.  Treatment: Decitabine (DAC) 0.5 - 1 µM or cytosine arabinoside 
(AraC) 0.5 µM on day 1, 4 and 7.  DAC 0.5µM depleted DNMT1 without causing measurable DNA damage 
(figure  S1).   A)  Non-DNA damaging DNMT1 depletion has opposite  effects  on the proliferation of 
normal and leukemia cells.  Cell counts by automated cell counter. B)  DAC did not increase apoptosis in 
normal or leukemia samples.  Apoptosis measured by flow-cytometry for annexin and 7AAD staining on Day 
5.  Similar results were noted in the leukemia samples.  C) DAC treated normal precursors retain primitive 
morphology while leukemia cells differentiate.  Giemsa stained cytospin preparations on day 9 of liquid 
culture.  D) DAC treatment of normal cells prolongs colony-forming ability, increases colony-size and 
mixed character, while abrogating colony formation by CD34 RUNX1-ETO.  Cells were plated in semisolid 
media without DAC after 7, 14 or 21 days in liquid culture (DAC treatment was stopped on day 7).  Phase-
contrast images of colonies.  U=Untreated, D=DAC treated, A=Ara-C treated. E) DAC treatment significantly 
decreases precursor-CpG methylation in normal but not leukemia cells.  Precursor and differentiation-
CpG as defined in text and figure 3 legend.  
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Figure 5
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Figure 5:  DNMT1 depletion with decitabine (DAC) induces terminal differentiation of leukemia cells 
containing a variety of chromosome abnormalities. A) DAC terminally differentiates MLL-AF9 leukemia 
cells.   MLL-AF9 (MA9)  leukemia-initiating  cells  are  produced  by  retroviral  transduction  of  CD34+ human 
hematopoietic  precursor  cells.   Some clones  are  additionally  transduced  to  express  leukemia  associated 
mutants  of  FLT3 (ITD)  and RAS (NRas).  These cells  self-renew indefinitely  in-vitro  and initiate  invasive 
leukemia in transplanted mice.  Cells were treated with DAC 0.5 µM added on days 1, 4 and 7.  Non-DNA 
damaging DNMT1 depletion was confirmed by immune-fluorescence and flow-cytometry  (figure S5).   Cell 
counts by automated cell counter.  Images: Giemsa-stained cytospins Day 9. B) DAC treated MLL-AF9 cells 
lose clonogenicity.  Colony formation by MLL-AF9 cells is a surrogate for their ability to initiate leukemia. 
Viable untreated (U) and DAC treated (D) cells were plated in semi-solid medium which did not contain DAC 
after 6 days of liquid culture.  C) DAC terminally differentiates primary leukemia cells from patients and 
leukemia cell-lines.  Primary leukemia cells were aspirated from the bone marrow of patients with AML and 
cultured  in  media  supplemented  with  cytokines  (SCF,  FLT-3,  TPO,  IL-3,  IL-6)  with  (full-lines)  or  without 
decitabine (dashed-lines) (DAC) (0.5 µM) added on day 1, 4 and 7.  These samples represent a spectrum of 
morphologic  classification  and  chromosome  abnormalities  (figure  S5).   Leukemia  cell  lines:  Erythro-
megakaryoblastic leukemia (UT7, K562).  Cell counts by automatic cell counter on day 8.  Images: day 8. 
MLL-AF9 and cell-line cell cultures were maintained until day 21 to confirm that there was no rebound increase 
in cell numbers after discontinuation of DAC treatment on day 7.   
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Figure 6
Figure 6:  A dose and schedule of decitabine that depletes DNMT1 but does not produce measurable 
DNA  damage  (1mg/m2  3X/wk  intra-peritoneal)  increases  survival  in  a  murine  xeno-transplantation 
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model  of  aggressive  human leukemia.   A-C)   In-vivo  depletion  of  DNMT1 without  DNA damage  was 
confirmed by measuring DNMT1 depletion in bone marrow cells using immune-fluorescence (red dots) (A) and 
DNA damage in bone marrow cells by flow-cytometric measurement of phosphorylation of H2AX (B). Grey = 
isotype control.  Mice were transplanted with 1x106 MLL-AF9 leukemia cells.  Mock treatment was with intra-
peritoneal PBS.  5 mice in each treatment group.   This regimen increased survival in the treated mice by 
approximately  20%  (C).   D) Two  pathways  for  persistent  self-renewal  that  ignores  differentiation-
inducing  signals,  and  the  therapeutic  implications.  Left  panel:  In  hematopoietic  stem  cells  (HSC), 
decitabine (DAC) to deplete DNMT1 and antagonize transcription repression prevents a necessary first step in 
lineage-commitment, which is repression of stem cell gene expression.  Therefore, daughter cells resemble the 
parental stem cell, even in differentiation promoting conditions.  If DAC is added shortly after the differentiation-
inducing stimulus (after the phase of stem cell associated gene repression), it does not prevent and may even 
increase differentiation.  Right  panel:  The cell  of  origin  (CO)  is  the  cell  that  sustains  the  first  genetic  or 
epigenetic abnormality leading to leukemia.  The CO could be a stem cell, however, abnormal self-renewal and 
leukemia initiating ability (LIC) may manifest in lineage-committed daughter cells, since the genetic/epigenetic 
abnormalities  may allow stem cell  gene repression but  impair  terminal  differentiation  gene activation that 
terminates transit-amplification.  In these cells, primed to differentiate with high levels of lineage-specifying 
factors, repression of stem cell genes, and with aberrant repression of differentiation genes that requires the 
transcription repression machinery, DAC terminates self-renewal and resumes differentiation.      
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Supporting Online Material
Tables (attached excel file)
S1 A:  Genes repressed >2-fold by micro-array gene expression analysis 6 hours after OHT (Pu.1) 
introduction to PUER cells
S1 B: Genes activated >2-fold by micro-array gene expression analysis 24 hours after OHT (Pu.1) 
introduction to PUER cells
S2A:  List of Precursor CpG (CpG that are significantly hypermethylated during hematopoietic 
differentiation)
S2B:  Differentiation CpG (CpG that are significantly hypomethylated during normal hematopoietic 
differentiation)
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Figure S1
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Figure S1.  The nucleoside analogue decitabine (DAC) can deplete DNMT1 without causing measurable 
DNA  damage.   A)   Increasing  levels  of  DAC  produce  increasing  DNMT1  depletion  in  normal 
hematopoietic precursor cells.  Normal CD34+ hematopoietic precursor cells were isolated from cord-blood. 
DAC concentration in µM, number of DAC additions in a 1 week period in parentheses.  DNMT1 was quantified 
by immuno-fluorescence using a Q-dot based secondary anti-body (red dots) and Image-Quant software. DAPI 
was used to stain nuclei (blue stain).  B & C) These levels of decitabine do not produce measurable DNA 
damage.  DNA damage was measured by flow-cytometric  assessment for  (B) phosphorylation of  histone 
H2AX or by (C) the Fast Micromethod for DNA scission 24 hours after DAC exposure.  Equimolar doses of 
another cytosine analogue, cytosine arabinoside (AraC) produce significant DNA damage.  Grey histogram = 
isotype control for flow-cytometric analysis.  D)  DAC, at these non-DNA damaging but DNMT1 depleting 
levels, produces transient cell-cycle arrest followed by rebound hyperproliferation.   Cell-cycle status 
was measured at  the various time-points  by flow-cytometric  assessment of  propidium iodide staining.   E) 
Kinetics  of  DNMT1  depletion  and  recovery  in  normal  hematopoietic  precursors  exposed  to  a  1X 
addition  of  DAC 0.5µM.   DNMT1 was  quantified  with  the  Q-dot  based  assay  (red  dots  –  appear  pink 
overlayed on blue DAPI stain). Nuclei are stained with DAPI (blue).  F) DAC can inhibit or enhance G-CSF 
mediated myeloid differentiation depending on the timing of DAC addition in relationship to the G-CSF 
stimulus.  G-CSF (100ng/ml) was added to CD34+ selected cord-blood cells cultured in media supplemented 
with SCF, FLT3, TPO, IL-3 and IL-6.  DAC (0.5µM) was added either concurrently with G-CSF or 6 hours after 
G-CSF.  Cells were plated into methyl-cellulose (20,000/ml methyl-cellulose) 9 days after the addition of G-
CSF/DAC.  Colonies were counted and photographed (phase-contrast) after 12 days of culture in methyl-
cellulose.  DAC added concurrent with G-CSF encourages formation of larger and mixed colonies, whereas 
DAC added 6 hours after G-CSF results in significantly decreased colony-forming ability and smaller colonies. 
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Figure S2
Figure S2:  Runx1 deficiency allowed OHT (Pu.1) mediated repression gene repression but impairs 
Pu.1  mediated  gene  activation.   A)  Microarray  gene  expression  analysis  was  used  to  identify  genes 
repressed early or activated more than 2-fold after Pu.1 introduction into control vector transduced PUER cells. 
The expression pattern of these repressed and activated genes (table S1) was compared in PUER shRunx1 at 
6 and 24h after Pu.1 introduction. B)  Colony forming units (CFU) in Runx1 +/-  and wild-type congenic murine 
bone marrow cells plated into methyl-cellulose (2x104 cells/ml) supplemented with cytokines to promote self-
renewal versus differentiation were counted at day 10.  After counting, colony cells were washed twice with 
PBS to remove methylcellulose and replated under identical conditions.  
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Figure S3
Figure  S3.   The  samples analyzed are  representative  of  the clinical  spectrum of  AML.   A)   WHO 
classification and detected chromosome abnormalities in AML CD34+ cells analyzed by RQ-PCR.  M5 = 
Acute monoblastic leukemia; M2 = Acute myeloblastic leukemia with maturation.  B)  WHO classification and 
detected chromosome abnormalities in MDS and AML bone marrow aspirate specimens analyzed by 
RQ-PCR.  RA = refractory anemia; RCMD = refractory cytopenia with multi-lineage dysplasia; RCMD-RST = 
refractory  cytopenia  with  multi-lineage  dysplasia,  ring  sideroblasts  and  thrombocytosis.   M1  =  Acute 
myeloblastic leukemia without maturation.  M4 = acute myelomonocytic leukemia.  
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Figure S4
Figure S4: Suppression of DNMT1 expression in Kasumi-1 cells using decitabine or siRNA induces 
terminal differentiation.  A) DAC significantly decreased the colony-forming ability of Kasumi-1 cells. 
Viable  Kasumi-1  cells  were  plated  into  methyl-cellulose  (2x103 cells/ml)  on  day  9  after  treatment  with 
decitabine 0.5µM on day 1 and 2.  Colonies were counted 12 days after plating. B). DNMT1 suppression by 
siRNA was confirmed by immuno-fluorescence measurement of DNMT1 levels.  Kasumi-1 cells were 
transfected with control siRNA to or siRNA to deplete DNMT1.  C) DNMT1 depletion by siRNA terminally 
differentiated  Kasumi-1  cells.   Cell-counts  measured  by  automatic  counter.  Images: Giemsa-stained 
cytospins 5 days after transfection. 
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Figure S5
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Figure  S5:  DNMT1  depletion  by  non-DNA  damaging  levels  of  decitabine  (DAC)  induces  terminal 
differentiation in leukemia cells containing a variety of chromosome abnormalities.  A) MLL-AF9 cells 
are CD34 negative, consistent with self-renewal in a post lineage commitment context.  MLL-AF9 (MA9) 
leukemia-initiating  cells  are produced by retroviral  transduction  of  CD34+ human hematopoietic  precursor 
cells, but self-renewing and leukemia-initiating cells are CD34 negative (measured by flow-cytometry).  Grey = 
isotype control.    B)  MA9 cells express high levels of lineage-specifying factors (CEBPα,  PU.1) and 
intermediate  levels  of  stem  cell  associated  factors  (HOXB4,  BMI-1)  compared  to  normal  CD34+ 
hematopoietic precursors.  Gene-expression by RQ-PCR.  C) Decitabine (DAC) 0.5µM on day 1, 4, and 7 
depletes DNMT1 without causing DNA damage.  DNMT1 levels measured by immuno-fluorescence (red-
dots).  DNA damage measured  by flow-cytometry for phospho-H2AX.  Positive control for DNA damage = 
cells  treated with  equimolar  concentration  of  AraC.   Grey  histogram = isotype control.   D)  Morphologic 
classification by WHO categories and metaphase cytogenetic analysis of primary leukemia samples 
treated with DAC.  M1 = Acute myeloblastic leukemia without maturation; M2 = Acute myeloblastic leukemia 
with  maturation;  M4  =  acute  myelomonocytic  leukemia;  M5  =  Acute  monoblastic  leukemia;  M6  =  Acute 
erythroid leukemia; M7 = acute megakaryoblastic leukemia.   
35
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
04
4.
1 
: P
os
te
d 
8 
Ap
r 2
00
9
Materials and Methods
Normal volunteer and patient samples: Umbilical cord blood was collected during normal full-term deliveries 
with  informed  consent  of  the  mother  on  a  CASE IRB approved  protocol.   Bone  marrow  aspirates  were 
collected from patients and healthy volunteers. Informed consent for sample collection was obtained according 
to protocols approved by the Cleveland Clinic IRB.  All these samples are associated with anonymized clinical 
hematopathology data that indicate the morphological classification and immuno-phenotype of the disease. 
Patients were grouped according to the World Health Organization (WHO) classification system.
Human hematopoietic cell culture:  Normal human hematopoietic cells, CD34 RUNX1-ETO cells, and MLL-
AF9 cells were cultured in IMDM supplemented with 10% fetal bovine serum and 10ng/ml of the following 
human cytokines: stem cell factor (SCF), FLT3 ligand (FLT3), thrombopoietin (TPO), interleukin-3 (IL-3) and 
interleukin-6 (IL-6). 
Isolation  of  CD34+  cells: CD34+  cells  from  umbilical  cord  blood  or  bone  marrow  aspirates  were 
immunopositively purified using a magnetic cell sorting system a CD34 MicroBead Kit (catalog #: 130-046-702, 
Miltenyi Biotec) according to manufacturer instructions. The purity of the CD34+ population (ranged typically 
from 95 to 99%) was determined by immunolabeling with FITC-conjugated monoclonal  antibodies against 
CD34 (Clone 581, Beckman Coulter, Miami, FL, USA) that reacted with an epitope other than the antibody 
used for separation.  
Generation of PUER cells with stable suppression of Runx1 or Dnmt1 expression:  A lentiviral vector 
pLenti6-DEST (Invitrogen, Carlsbad, CA) was used to construct short hairpin (sh) RNA for Runx1 and Dnmt1. 
The  specific  21-bp  target  sequences  for  mouse  shRunx1  (5 -TGTGGATGACTGAGTACCTGA-3 )  and′ ′  
mouse shDnmt1 (5 -GAACGGCATCAAGGTGAAC-3 ) were synthesized in sense and antisense orientation′ ′  
by Advanced DNA Technology (ADT),  the single-strand oligos were then annealed to  form double-strand 
oligos,  and subsequently  ligated  with  pENTRY vector  (Invitrogen,  Carlsbad,  CA)  downstream of  an  RNA 
promoter.  The ligated constructs were transformed into E. Coli TOPO10.  Positive clones were verified by 
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DNA sequencing.   The verified clones were then recombined into pLenti6-DEST vector  using Invitrogen’s 
ViralPack  kit,  resulting  in  pLenti6-shRunx1  and  pLenti6-Dnmt1.  The  pLenti6-shRunx1  and  pLenti6-Dnmt1 
constructs were then transfected together with envelop encoding plasmid (VSVG) into 293FT packaging cell 
line to produce lentivirus.  The supernatant containing lentivirus was harvested at 48 hours after transfection. 
Titers were determined on NIH3T3 cells as transducing units using serial dilutions of vector stocks with 8 µg/ml 
polybrene (Sigma Chemical, St. Louis, MO). 
PUER cells (kindly provided by Dr. Harinder Singh, University of Chicago) are murine hematopoietic 
precursor cells that have been retrovirally transduced to express Pu.1 fused to the estrogen receptor.  To 
knock-down Runx1 and Dnmt1 in cells, murine PUER cells were grown in Iscove's modified Eagle's medium, 
without phenol-red, with 10% fetal bovine serum, 2.5ng/ml mouse IL-3, 1 g/ml Puromycin, 55 M beta-ME, 1%μ μ  
penicillin/streptomycin  at  37°C  in  a  humidified  atmosphere  with  5% CO2 in  air.  The  lentivirus-containing 
supernatant was added to the cell culture at appropriate 4 particles/cell concentration with 8 µg/ml polybrene. 
Twenty-four hours after infection, 4ug/ml of blasticidin (bln) was added to the cell culture for positive clone 
selection. The Bln-resistant cells were analyzed for Runx1 and Dnmt1 expression by RQ-PCR and Western 
blot.  
Addition  of  tamoxifen  (OHT)  to  PUER  triggers  their  terminal  differentiation  into  macrophages  . 
Differentiation status was analyzed by: (i) presence of adherent cells by light microscopy, (ii) morphological 
changes in Giemsa stained cytospin preparations, and (iii) cKit (eBioscience catalog number 11-1171-82) and 
F4/80 (eBioscience catalog number 15-4801-82) expression by flow cytometry.
Real time PCR (RQ-PCR): mRNA levels were assayed using RQ-PCR.  Briefly, total cellular RNA is isolated from 
5x105 cells using RNeasy Plus (QIAGEN), according to the manufacturer's protocol.  For cDNA synthesis, after a 
denaturation step of 5 min at 70°C, 1 g of RNA were reverse transcribed to single-stranded cDNA using a mix ofμ  
random hexamers and oligo dT primers and M-MLV reverse transcriptase for first strand synthesis (Promega). 
Real-time PCR was performed with Real-time PCR Master Mix containing Sybrgreen I and hotstart Taq DNA 
polymerase (Takara). GAPDH was amplified as control.  Primer sequences available upon request.  Real-time 
detection of the emission intensity of SYBR Green bound to double-stranded DNA will be detected using the iCycler 
instrument (Bio-Rad). 
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Micro-array gene expression analysis:  Total cellular RNA was isolated from PUER and PUER-shRunx1 cells, 
at base-line and 6 and 24 hours after OHT addition,using a RNeasy Kit (Cat#74104, Qiagen GmbH, Hilden, 
Germany) per manufacture’s instruction.  The purity, concentration and quality of the RNAs were determined 
using  a  NanoDrop  spectrophotometer  and  agarose  gel  electropherosis.   All  the  RNA  samples  had  an 
A260/280>1.8 and A260/A230>1.8, with intact 28S and 18S ribosome RNA visible on 1% agarose gel.
20 g of RNA from each sample was submitted to NimbleGen (Roche NimbleGen Inc, Iceland) for gene-μ
expression  microarray  analysis.  At  NimbleGen,  double-stranded  cDNA  was  synthesized  from  each  RNA 
sample using Invitrogen Superscript Double-Stranded cDNA Synthesis Kit. The cDNAs were then labeled with 
Cy3 and used for hybridization with array. 385K 1-plex arrays were used in the experiments. Gene-expression 
data from the array experiments were analyzed using ArrayStar 2 software (DNAStar, Inc).
Quality controlled raw data (Affymetrix CEL files or SOFT files for GDS2118 dataset) from previously 
published experiments (references GDS2118, GSE123326, GSE1159, GSE9476, GSE1729, GDS1064   ) was 
downloaded from Gene Expression Omnibus (GEO) datasets (www.ncbi.nlm.nih.gov/geo).  Log2  expression 
values  for  individual  probe  sets  utilizing  the  same  micro-array  platform  were  combined  using  RMA 
normalization supplemented with the median over the entire array method (BRM-ArrayTools  version 3.7.1 
developed by Dr. Richard Simon and BRB-ArrayTools Development Team).  By comparing ratios of gene 
expression  that  were  calculated  within  each  sample  (CEBPα/HOXB4  expression  and  CEBPε/CEBPα 
expression)  the  gene  expression  data  was  also  internally  controlled.   Heat-maps  were  generated  using 
ArrayStar®  v3.0 (DNASTAR, Madison, WI).
Methylome analysis: 1 µg of DNA extracted using the Pure-Gene kit was subject to analyses by the Cancer 
Methylation Panel 1 (1505 selected CpG sites) in the Golden Gate Assay kit (Illumina) following the protocol 
provided with the kit.  Briefly, bisulfite conversion of DNA samples is done using the EZ DNA methylation kit 
(Zymo  Research).  For  each  CpG  site,  there  are  two  pairs  of  probes  which  corresponded  to  either  the 
methylated  or  unmethylated  state  of  the  CpG  site.  Through  allele-specific  extension  and  ligation,  PCR 
templates  are  generated  and  then  amplified  by  PCR  using  fluorescently  labeled  common  primers.  The 
resulting PCR products are hybridized to a bead array at sites bearing a complementary address sequence. 
These hybridized targets contain a fluorescent label that denotes a methylated or unmethylated state for a 
given locus.  Methylation status of the interrogated CpG site is then calculated as the ratio of fluorescent signal 
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from one allele relative to the sum of both methylated and unmethylated alleles. The image extraction and 
statistical analysis is done with Beadstudio Methylation Module Software (Illumina).  The -value provides aβ  
continuous measure of levels of DNA methylation at a CpG site, ranging from 0 in the case of completely 
unmethylated sites to 1 in completely methylated sites.  
Clonogenic progenitor assays: Cells in liquid culture were treated with decitabine on day 1, 4 and 7.  After 7, 14 
or 21 days in liquid culture, identical numbers of cells from treated and untreated control samples  (20,000/ml 
methyl-cellulose of normal,  RUNX1-ETO CD34+ cells and MLL-AF9 cells,  and 2000/ml methyl-cellulose of 
Kasumi-1  cells)  are  plated  in  decitabine  free-semisolid  media  (MethoCult  H4434,  Stem  Cell  Technology) 
supplemented with SCF (50 ng/mL), GM-CSF (10 ng/mL), IL-3 (10 ng/mL), and erythropoietin (3 U/mL).  Different 
colony-forming units (CFU) were identified by morphology and counted under an inverted microscope at 10 to 12 
days post-plating.
Immunofluorescence with Q-Dots to  measure DNMT1 levels:  Cells  on cytospin  slides  were  fixed and 
permeabilized with 10% formalin and 0.25% triton.  Non specific binding sites were blocked with 10% normal 
goat serum and 6% BSA. Slides were incubated overnight with mouse anti-DNMT1 antibody (Abcam catalog 
number ab13537) (diluted 1:500 in blocking solution), followed by a 655 nm Quantum DotsTM-conjugated goat 
anti-mouse  antibody  (Invitrogen  catalog  number  Q11022MP)  (diluted  1:500).  Finally,  cells  were  stained 
with 3 µM DAPI for 5 min before dehydration in graded alcohols and xylene.  Image files were loaded into the 
Image-Pro Plus environment and individual cells were segmented for quantification of fluorescence signal with 
the "count/size" function of Image-Pro Plus.  Precise segmentation was achieved by setting a lower threshold 
just  above  background  emission.   A  filter  was  set  for  an  area  of  whole  cells  and  excluded  fluorescent 
fragments from the measurement.   Image-Pro Plus generates a high-content  array of  measurements that 
include event number, area, mean of pixel intensities, and maximum and minimum pixel intensities. These 
scores were integrated into a mean intensity fluorescence (MIF) score.  An MIF 25% of untreated control is≤  
the threshold that was used to evaluate decitabine effectiveness.  
DNA damage measurement by Fast Micromethod®: The Fast Micromethod DNA single-strand break assay 
is applied as described in Schroder H et al. Methods in Molecular Biology 2006; 314: 287-305.  The method is 
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based on the ability of the specific fluorochrome dye PicoGreen® to make a stable complex with dsDNA, but 
not ssDNA in highly alkaline conditions. Cells (3000 cells/25 µl) were incubated in lysis buffer (4.5 M urea, 0.2 
M EDTA, 0.1% SDS, pH 10.0) supplemented with PicoGreen® (Invitrogen). DNA denaturation is triggered by 
addition  of  NaOH–EDTA  solution  (pH  =  12)  and  recorded  after  20  min  by  measuring  the  fluorescence 
(excitation 485 mn/emission 520 nm) of the ssDNA-PicoGreen complex.  Results are expressed as strand 
scission factors (SSF), calculated as the log10 of the ratio of the percentage of ssDNA from treated and control 
samples, respectively, after 20 min of denaturation.  For practical reasons to facilitate display of the data, the 
SSF are multiplied by -1.
DNA damage measurement by γH2AX staining: Phosphorylation of the histone H2A family member H2AX at 
Ser139 (γH2AX) was measured by flow cytometry.  Cells were fixed  with 2% paraformaldehyde and then 
permeabilized by adding an iced cold 90% methanol solution. Cells were then incubated in blocking solution 
(0.5% BSA)  containing  saturating  concentration  of  Alexa  488-conjugated  γH2AX  antibody  (Cell  signaling 
technology catalog number 9719).  Percentage of  γH2AX positive cells is analyzed by using a Coulter Epics 
XL-MCL flow cytometer equipped with CXP software (Beckman-Coulter). 
Cell  cycle  analysis:   Cell  cycle status in  normal  CD34+ cells  after  a single exposure to  decitabine was 
analyzed by measuring single cell DNA quantity.  Cells were harvested at different time points and incubated 
with 100 mg/ml propidium iodide (Sigma) and 0.2 mg/ml DNase-free RNaseA (Boehringer Mannheim). After 30 
minutes, single cell DNA content was analyzed by flow-cytometry.
Apoptosis  detection:   Apoptosis  was  detected  by  Annexin-V  and  7AAD  co-staining  using  the  APOAF 
commercial  kit  (Sigma).  Cells  (5x105) were  washed  and  incubated  for  30  minutes  with  FITC-conjugated 
Annexin-V at room temperature. Cells were then resuspended in 400 mL of binding buffer containing 7AAD 
and immediately analyzed by flow cytometry.
Flow cytometry studies: Cell analysis was performed on a Coulter Epics XL-MCL flow cytometer equipped 
with CXP software (Beckman-Coulter).  Kasumi or CD34+ cord blood cells were stained for 20 min with a 
combination of fluorochrome-conjugated monoclonal antibodies for CD34, CD38, CD90, CD33 and/or CD133. 
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The CD90 antibody (catalog #:  IM1840U) was purchased from Coulter/Immunotech.  The CD133 antibody 
(catalog #: 130-080-801) was from MACS (Miltenyi Biotec). The antibodies against CD34, CD38, and CD33 
(catalog #: 348053, 340409, and 347787 respectively) were from Becton Dickinson. For each mAb, an isotype-
matched immunoglobulin was used as a control in all experiments. The percentage of CD90+, CD33+ and 
CD133+ positive cells was assessed in the CD34+CD38- subpopulation. 
Murine studies:  The MLL-AF9 xeno-transplantation experiments were approved by the Cincinnati Children’s 
Hospital Medical Center (CCHMC) Animal Care and Use Committee (IACUC).  Cultured MLL-AF9 (MA9) cells 
(1x106) were transplanted by intrafemoral injection into non-irradiated 6-8 week old NOD/SCID mice.  Mice 
were anesthetized with isofluorane before transplantation.  Animals were checked daily by a technician in the 
animal laboratory.  Animals were euthanized if they developed signs of distress.  Euthanasia was performed by 
cervical  dislocation  under  CO2 asphyxiation  as  approved  by  the  IACUC  and  consistent  with  the 
recommendations of the panel on Euthanasia of the Animal Veterinary Medical Association.  Decitabine was 
administered  via  the  intra-peritoneal  route  at  a  dose  of  0.3mg/kg  (1mg/m2)  3X/week  (Mon,  Thurs,  Fri) 
beginning in week 2 after transplantation.  Bone marrow cells obtained after euthanasia were assessed for 
DNMT1 depletion  by immuno-fluorescence and DNA damage by  flow-cytometric  measurement  of  γH2AX. 
Survival  analyses  were  performed  by  Kaplan-Meier  analyses  with  the  log-rank  tests  and  p<0.05  was 
considered to be statistically significant.  
Wild type and RUNX1+/- C57BL/6 mice were a kind gift of Jim Downing and Noel Lenny of the Downing 
laboratory.  The  breeding protocol  was approved by the Cleveland Clinic Animal Care and Use Committee 
(IACUC).  Animals were euthanized by cervical dislocation after CO2 asphyxiation.  RNA isolation for RQ-PCR 
experiments was performed from bone marrow cells obtained after euthanasia. Bone marrow cells were also 
seeded in liquid culture under self renewal (50 ng/ml murine SCF and 100 ng/ml human TPO) or differentiation 
inducing condition (50 ng/ml murine SCF, 10 ng/ml murine IL-6 and 20 ng/ml human GCSF).  Cell counts were 
performed every 48 h.  Clonogenic progenitor assays (MethoCult GF M3434; Stem Cell Technologies) were 
performed in triplicate under self renewal and differentiation inducing conditions at a density 2 x 104 cells/ml 
methyl-cellulose. The number of colonies was scored after 10 days. After counting, colony cells were washed 
twice with PBS to remove methylcellulose and then subsequently replated under identical conditions. 
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